GSK Is First To Share Cancer Drug Patents With Poor Countries
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline to license its future cancer treatments for generic manufacturing in poor countries; access continues to be flagship issue for GSK's Witty, who also sits on recently formed UN access panel.
You may also be interested in...
More Pressure On Pharma: UN Report Backs Compulsory Licensing
Heavy-weight United Nations panel makes tough recommendations favoring compulsory licensing – an issue that has riled Big Pharma but has at least one industry proponent, Cipla's chair Yusuf Hamied, who talked to the Pink Sheet about the "excesses" of intellectual property rights.
FTC Commissioner Recusal Decisions Should Be Public, US Chamber Of Commerce Says
Chamber files petition to have FTC amend its disqualification rules to have commissioners explain their rejection of recusal requests. FTC is seeking public comments on the petition.
FTC Merger Guidelines Cast ‘Perilous Shadow’ Over Biopharma
BIO objects to guidelines seeking to block mergers that would eliminate a potential entrant in a concentrated market and give greater scrutiny to transactions that are part of a series of company deals. APhA and NCPA call for FTC to consider more factors in PBM mergers.